Thoms, Kai-Martin

[["dc.bibliographiccitation.firstpage","324"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Dermatology"],["dc.bibliographiccitation.lastpage","328"],["dc.bibliographiccitation.volume","226"],["dc.contributor.author","Kaune, Kjell Matthias"],["dc.contributor.author","Haas, Ellen"],["dc.contributor.author","Jantke, Maren"],["dc.contributor.author","Kramer, Franz-Josef"],["dc.contributor.author","Gruber, Rudolf"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Zutt, Markus"],["dc.contributor.author","Schön, Michael P."],["dc.date.accessioned","2018-11-07T09:29:38Z"],["dc.date.available","2018-11-07T09:29:38Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Concepts of reconstruction of intraoral structures may often include the transfer of flaps composed of external skin with hairs. Given that intraoral hair growth following myocutaneous flaps can cause discomfort, there is a need for effective treatments to relieve cancer patients of these symptoms. Objective: To describe the successful epilation of hairy intraoral flaps using Nd:YAG laser emitting a wavelength of 1,064 nm. Methods: We performed an interdisciplinary prospective clinical study with 9 patients suffering from intraoral hair growth after plastic reconstruction of a hairy donor site due to cancer. Eight male and one female patients were treated with 1-4 sessions of Nd:YAG laser at 5-15-week intervals. Results: Laser treatment resulted in effective hair reduction in 8/9 patients regardless of flap type. In 5/9 patients a hair clearance of > 90% could be achieved, whereas laser treatment was ineffective in one male with white hair. Patients were very satisfied with the outcome and no side effects could be observed. Conclusion: Nd:YAG laser therapy appears to be a successful therapeutic option for patients suffering from growth of dark hair in the oral cavity after plastic reconstruction using a hairy donor site. (C) 2013 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000350685"],["dc.identifier.isi","000324547600007"],["dc.identifier.pmid","23838394"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10820"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31086"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9832"],["dc.relation.issn","1018-8665"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Successful Nd:YAG Laser Therapy for Hair Removal in the Oral Cavity after Plastic Reconstruction Using Hairy Donor Sites"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3359"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Koch, Elias; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, elias.koch@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, elias.koch@uk-erlangen.de"],["dc.contributor.affiliation","Petzold, Anne; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Anne.Petzold@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Anne.Petzold@uk-erlangen.de"],["dc.contributor.affiliation","Wessely, Anja; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Anja.Wessely@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Anja.Wessely@uk-erlangen.de"],["dc.contributor.affiliation","Dippel, Edgar; \t\t \r\n\t\t Department of Dermatology, Ludwigshafen Medical Center, 67059 Ludwigshafen, Germany, dippele@klilu.de"],["dc.contributor.affiliation","Gesierich, Anja; \t\t \r\n\t\t Department of Dermatology, University Hospital Würzburg, 97080 Würzburg, Germany, gesierich_a@ukw.de"],["dc.contributor.affiliation","Gutzmer, Ralf; \t\t \r\n\t\t Skin Cancer Center Minden, Department of Dermatology, Mühlenkreiskliniken AöR, Ruhr University Bochum Campus Minden, 32423 Minden, Germany, Ralf.Gutzmer@ruhr-uni-bochum.de"],["dc.contributor.affiliation","Hassel, Jessica; \t\t \r\n\t\t Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany, Jessica.Hassel@med.uni-heidelberg.de"],["dc.contributor.affiliation","Haferkamp, Sebastian; \t\t \r\n\t\t Department of Dermatology, University Hospital Regensburg, 93053 Regensburg, Germany, sebastian.haferkamp@ukr.de"],["dc.contributor.affiliation","Hohberger, Bettina; \t\t \r\n\t\t Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Bettina.Hohberger@uk-erlangen.de"],["dc.contributor.affiliation","Kähler, Katharina; \t\t \r\n\t\t Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany, kckaehler@yahoo.de"],["dc.contributor.affiliation","Knorr, Harald; \t\t \r\n\t\t Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Harald.Knorr@uk-erlangen.de"],["dc.contributor.affiliation","Kreuzberg, Nicole; \t\t \r\n\t\t Department of Dermatology and Venereology, Skin Cancer Center at the Center of Integrated Oncology (CIO) Köln Bonn, University Hospital of Cologne, 50937 Cologne, Germany, nicole.kreuzberg@uk-koeln.de"],["dc.contributor.affiliation","Leiter, Ulrike; \t\t \r\n\t\t Department of Dermatology, Center for Dermatooncology, University Hospital Tübingen, 72056 Tübingen, Germany, Ulrike.Leiter@med.uni-tuebingen.de"],["dc.contributor.affiliation","Loquai, Carmen; \t\t \r\n\t\t Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany, carmen.loquai@unimedizin-mainz.de"],["dc.contributor.affiliation","Meier, Friedegund; \t\t \r\n\t\t Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases & Department of Dermatology, University Hospital Carl Gustav Carus, 01307 Dresden, Germany, Friedegund.Meier@uniklinikum-dresden.de"],["dc.contributor.affiliation","Meissner, Markus; \t\t \r\n\t\t Department of Dermatology, Venereology and Allergology, Goethe University, 60590 Frankfurt am Main, Germany, markus.meissner@kgu.de"],["dc.contributor.affiliation","Mohr, Peter; \t\t \r\n\t\t Department of Dermatology, Elbeklinikum, 21614 Buxtehude, Germany, peter.mohr@elbekliniken.de"],["dc.contributor.affiliation","Pföhler, Claudia; \t\t \r\n\t\t Department of Dermatology, Saarland University Medical School, 66421 Homburg/Saar, Germany, claudia.pfoehler@uks.eu"],["dc.contributor.affiliation","Rahimi, Farnaz; \t\t \r\n\t\t Department of Dermatology and Allergy, Munich University Hospital (LMU), 81377 Munich, Germany, Farnaz.Rahimi@med.uni-muenchen.de"],["dc.contributor.affiliation","Schadendorf, Dirk; \t\t \r\n\t\t Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany, Dirk.Schadendorf@uk-essen.de\t\t \r\n\t\t German Cancer Consortium, Partner Site Essen, 45147 Essen, Germany, Dirk.Schadendorf@uk-essen.de"],["dc.contributor.affiliation","Schell, Beatrice; \t\t \r\n\t\t Department of Dermatology, SRH Wald-Klinikum Gera, 07548 Gera, Germany, Beatrice.Schell@srh.de"],["dc.contributor.affiliation","Schlaak, Max; \t\t \r\n\t\t Department of Dermatology, Venerology and Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany, max.schlaak@charite.de"],["dc.contributor.affiliation","Terheyden, Patrick; \t\t \r\n\t\t Department of Dermatology, University of Lübeck, 23562 Lübeck, Germany, patrick.terheyden@uksh.de"],["dc.contributor.affiliation","Thoms, Kai-Martin; \t\t \r\n\t\t Department of Dermatology, University Medical Center Goettingen, 37075 Goettingen, Germany, kai.thoms@med.uni-goettingen.de"],["dc.contributor.affiliation","Schuler-Thurner, Beatrice; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Beatrice.Schuler-Thurner@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Beatrice.Schuler-Thurner@uk-erlangen.de"],["dc.contributor.affiliation","Ugurel, Selma; \t\t \r\n\t\t Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany, Selma.Ugurel@uk-essen.de"],["dc.contributor.affiliation","Ulrich, Jens; \t\t \r\n\t\t Department of Dermatology, Harzklinikum Dorothea Christiane Erxleben, 06484 Quedlinburg, Germany, jens.ulrich@harzklinikum.com"],["dc.contributor.affiliation","Utikal, Jochen; \t\t \r\n\t\t Skin Cancer Unit, German Cancer Research Center (DKFZ), 68167 Heidelberg, Germany, Jochen.Utikal@umm.de\t\t \r\n\t\t Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany, Jochen.Utikal@umm.de"],["dc.contributor.affiliation","Weichenthal, Michael; \t\t \r\n\t\t Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany, mweichenthal@dermatology.uni-kiel.de"],["dc.contributor.affiliation","Ziller, Fabian; \t\t \r\n\t\t Department of Dermatology, DRK Krankenhaus Rabenstein, 09117 Chemnitz, Germany, Ziller.Fabian@drk-khs.de"],["dc.contributor.affiliation","Berking, Carola; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Carola.Berking@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Carola.Berking@uk-erlangen.de"],["dc.contributor.affiliation","Heppt, Markus; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Markus.Heppt@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Markus.Heppt@uk-erlangen.de"],["dc.contributor.author","Koch, Elias"],["dc.contributor.author","Petzold, Anne"],["dc.contributor.author","Wessely, Anja"],["dc.contributor.author","Dippel, Edgar"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Hassel, Jessica"],["dc.contributor.author","Haferkamp, Sebastian"],["dc.contributor.author","Hohberger, Bettina"],["dc.contributor.author","Heppt, Markus"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Kähler, Katharina"],["dc.contributor.author","Knorr, Harald"],["dc.contributor.author","Kreuzberg, Nicole"],["dc.contributor.author","Leiter, Ulrike"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Meissner, Markus"],["dc.contributor.author","Mohr, Peter"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Rahimi, Farnaz"],["dc.contributor.author","Schadendorf, Dirk"],["dc.contributor.author","Schell, Beatrice"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Schuler-Thurner, Beatrice"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Ulrich, Jens"],["dc.contributor.author","Utikal, Jochen"],["dc.contributor.author","Weichenthal, Michael"],["dc.contributor.author","Ziller, Fabian"],["dc.contributor.author","Berking, Carola"],["dc.contributor.authorgroup","on behalf of the German Dermatologic Cooperative Oncology Group (DeCOG, Committee Ocular Melanoma)"],["dc.date.accessioned","2021-08-12T07:45:52Z"],["dc.date.available","2021-08-12T07:45:52Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:20:46Z"],["dc.description.abstract","Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only."],["dc.description.abstract","Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only."],["dc.identifier.doi","10.3390/cancers13133359"],["dc.identifier.eissn","2072-6694"],["dc.identifier.pii","cancers13133359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88565"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Heppt, Markus V."],["dc.contributor.author","Amaral, Teresa"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Heinzerling, Lucie"],["dc.contributor.author","Hassel, Jessica C."],["dc.contributor.author","Meissner, Markus"],["dc.contributor.author","Kreuzberg, Nicole"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Reinhardt, Lydia"],["dc.contributor.author","Utikal, Jochen"],["dc.contributor.author","Dabrowski, Evelyn"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Eigentler, Thomas K."],["dc.contributor.author","Kirchberger, Michael C."],["dc.contributor.author","Stege, Henner M."],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Berking, Carola"],["dc.date.accessioned","2020-12-10T18:41:23Z"],["dc.date.available","2020-12-10T18:41:23Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s40425-019-0800-0"],["dc.identifier.eissn","2051-1426"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16952"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77565"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","505"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","508"],["dc.bibliographiccitation.volume","18"],["dc.contributor.affiliation","Brunnert, Fiona; 1\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Erpenbeck, Luise; 1\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Vlahova, Lyubomira; 1\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Kowallick, Johannes T.; 2\r\nInstitute for Diagnostic and Interventional Radiology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Thoms, Kai‐Martin; 1\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.affiliation","Schön, Michael P.; 1\r\nDepartment of Dermatology\r\nVenereology and Allergology\r\nUniversity Medical Center\r\nGöttingen Germany"],["dc.contributor.author","Brunnert, Fiona"],["dc.contributor.author","Erpenbeck, Luise"],["dc.contributor.author","Vlahova, Lyubomira"],["dc.contributor.author","Kowallick, Johannes T."],["dc.contributor.author","Thoms, Kai‐Martin"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Mitteldorf, Christina"],["dc.date.accessioned","2021-04-14T08:26:37Z"],["dc.date.available","2021-04-14T08:26:37Z"],["dc.date.issued","2020"],["dc.date.updated","2022-11-11T13:13:44Z"],["dc.identifier.doi","10.1111/ddg.14082"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82016"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Painful induration of the thigh"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e1433"],["dc.bibliographiccitation.issue","36"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","Kretschmer, Lutz"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Zapf, Antonia"],["dc.contributor.author","Mitteldorf, Christina"],["dc.contributor.author","Satzger, Imke"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Voelker, Bernward"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Starz, Hans"],["dc.date.accessioned","2018-11-07T09:51:53Z"],["dc.date.available","2018-11-07T09:51:53Z"],["dc.date.issued","2015"],["dc.description.abstract","The objective of this study was to analyze different types of nodal basin recurrence after sentinel lymph node biopsy (SLNB) for melanoma.Patients and Methods: Kaplan-Meier estimates and the Cox proportional hazards model were used to study 2653 patients from 3 German melanoma centers retrospectively.The estimated 5-year negative predictive value of SLNB was 96.4%. The estimated false-negative (FN) rates after 1, 2, 3, 5, and 10 years were 2.5%, 4.6%, 6.4%, 8.7%, and 12.6%, respectively. Independent factors associated with false negativity were older age, fewer SLNs excised, and head or neck location of the primary tumor. Compared with SLN-positive patients, the FNs had a significantly lower survival. In SLN-positive patients undergoing completion lymphadenectomy (CLND), the 5-year nodal basin recurrence rate was 18.3%. The recurrence rates for axilla, groin, and neck were 17.2%, 15.5%, and 44.1%, respectively. Significant factors predicting local relapse after CLND were older age, head, or neck location of the primary tumor, ulceration, deeper penetration of the metastasis into the SLN, tumor-positive CLND, and >2 lymph node metastases. All kinds of nodal relapse were associated with a higher prevalence of in-transit metastases.The FN rate after SLNB steadily increases over the observation period and should, therefore, be estimated by the Kaplan-Meier method. False-negativity is associated with fewer SLNs excised. The beneficial effect of CLND on nodal basin disease control varies considerably across different risk groups. This should be kept in mind about SLN-positive patients when individual decisions on prophylactic CLND are taken."],["dc.identifier.doi","10.1097/MD.0000000000001433"],["dc.identifier.isi","000369531900012"],["dc.identifier.pmid","26356697"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13119"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36000"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma A Retrospective Multicenter Study in 2653 Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","984"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","993"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Hartmann, Franziska"],["dc.contributor.author","Lockmann, Anike"],["dc.contributor.author","Himpel, Okko"],["dc.contributor.author","Kühnle, Ingrid"],["dc.contributor.author","Hensen, Janina"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Thoms, Kai‐Martin"],["dc.date.accessioned","2021-04-14T08:22:56Z"],["dc.date.available","2021-04-14T08:22:56Z"],["dc.date.issued","2020"],["dc.description.abstract","Summary Background and aims Infantile hemangiomas can be successfully treated by both systemic propranolol and neodymium:YAG (Nd:YAG)‐dye laser combination therapy. In this retrospective study, the efficacy and safety of sequential and parallel therapy of complicated hemangiomas treated with both methods were evaluated. Patients and methods 30 children with 48 complicated hemangiomas were treated with propranolol and Nd:YAG‐dye laser combination therapy. Using photo comparison, the percentage remission rate was evaluated by three investigators on a four‐step scale (I: 0–25 %, II: 26–50 %, III: 51–75 % and IV: 76–100 %). Results Eleven children received propranolol and laser therapy in parallel (A), twelve children received laser therapy after propranolol (B) and seven children received propranolol after laser therapy (C). Due to emigration abroad, one child was lost to follow‐up. A strong improvement (IV) was observed in 23/29 (79.3 %) of all treated children (A: 90.9 %, B 75 %, C 66.7 %). The mean duration of propranolol therapy in all children was 8.6 months (A: 8.9 months, B: 8.2 months, C: 8.9 months). On average, 2.33 laser treatments were performed per hemangioma (A: 1.95, B: 3.2, C: 1.91). Serious side effects caused by propranolol and laser therapy were not observed. Conclusions Propranolol and Nd:YAG‐dye laser combination therapy can be used sequentially or in parallel safely and effectively. They complement each other in a meaningful manner."],["dc.identifier.doi","10.1111/ddg.14184"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80739"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]